ARVN
Arvinas Inc
NASDAQ: ARVN · HEALTHCARE · BIOTECHNOLOGY
$9.90
+0.81% today
Updated 2026-04-30
Market cap
$667.75M
P/E ratio
—
P/S ratio
2.54x
EPS (TTM)
$-1.14
Dividend yield
—
52W range
$6 – $15
Volume
0.9M
Arvinas Inc (ARVN) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-30.80%
Operating margin
-755.00%
ROE
-16.20%
ROA
-7.94%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2016 | $6.67M | $-14.35M | 100.00% | -246.95% | -215.18% |
| 2017 | $7.58M | $-24.05M | 100.00% | -326.70% | -317.32% |
| 2018 | $14.32M | $-41.48M | 100.00% | -305.80% | -289.59% |
| 2019 | $42.98M | $-62.13M | 100.00% | -119.89% | -144.57% |
| 2020 | $21.80M | $-111.79M | 100.00% | -572.69% | -512.74% |
| 2021 | $46.70M | $-183.20M | 100.00% | -418.20% | -392.29% |
| 2022 | $131.40M | $-271.90M | 100.00% | -200.30% | -206.93% |
| 2023 | $78.50M | $-367.30M | 100.00% | -511.46% | -467.90% |
| 2024 | $263.40M | $-198.90M | 100.00% | -94.99% | -75.51% |
| 2025 | $262.60M | $-80.80M | 98.02% | -43.75% | -30.77% |